ALSO NOTED: Sanofi drug better for clots; FDA OKs generic anticonvulsive; and much more...

> An international study has concluded that Sanofi's Lovenox is more effective than an older, cheaper therapy in treating paralyzed stroke victims at risk of a second blood clot. Report

> The FDA has given its tentative approval to Abraxis' generic version of Pfizer Inc.'s anticonvulsant Cerebyx. Report

> Addex Pharmaceuticals announced today the successful completion of a Phase IIa proof of concept trial with its lead compound ADX10059 in patients with migraine. Release

> Boston's Massachusetts General Hospital (MGH) has raked in a giant $284 million windfall on royalty rights for foreign sales of Enbrel. Report

> Working with physician groups, AstraZeneca has begun an initiative intended to bring more minority doctors on board for drug trials. Report

And Finally... A new study involving dogs highlights the health benefits of calorie restriction. Report 

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.